Health-state utilities in long-term advanced melanoma survivors comparable with the general population.
Saved in:
| Title: | Health-state utilities in long-term advanced melanoma survivors comparable with the general population. |
|---|---|
| Authors: | Egeler, M. D. (AUTHOR), van de Poll-Franse, L. V. (AUTHOR), Tissier, R. (AUTHOR), Rogiers, A. (AUTHOR), Boers-Sonderen, M. J. (AUTHOR), van den Eertwegh, A. J. (AUTHOR), Hospers, G. A. (AUTHOR), de Groot, J. W. B. (AUTHOR), Aarts, M. J. B. (AUTHOR), Kapiteijn, E. (AUTHOR), Piersma, D. (AUTHOR), Vreugdenhil, G. (AUTHOR), van der Veldt, A. A. (AUTHOR), Suijkerbuijk, K. P. M. (AUTHOR), Neyns, B. (AUTHOR), Janssen, K. J. (AUTHOR), Blank, C. U. (AUTHOR), Retèl, V. P. (AUTHOR), Boekhout, A. H. (AUTHOR) |
| Source: | Quality of Life Research. Sep2023, Vol. 32 Issue 9, p2517-2525. 9p. 4 Charts. |
| Subjects: | Melanoma, Quality-adjusted life years, Overall survival |
| Abstract: | Background: Checkpoint inhibitors have been shown to substantially improve the survival of patients with advanced melanoma. With this growing group of survivors treated with immunotherapies, assessing their health-state utilities is essential and can be used for the calculation of quality-adjusted life years and for cost-effectiveness analyses. Therefore, we evaluated the health-state utilities in long-term advanced melanoma survivors. Methods: Health-state utilities were evaluated in a cohort of advanced melanoma survivors 24–36 months (N = 37) and 36-plus months (N = 47) post-ipilimumab monotherapy. In addition, the health-state utilities of the 24–36 months survivor group were assessed longitudinally, and utilities of the combined survival groups (N = 84) were compared with a matched control population (N = 168). The EQ-5D was used to generate health-state utility values, and quality-of-life questionnaires were used to establish correlations and influencing factors of utility scores. Results: Health-state utility scores were similar between the 24–36 months'- and the 36-plus months' survival group (0.81 vs 0.86; p =.22). In survivors, lower utility scores were associated with symptoms of depression (β = −.82, p =.022) and fatigue burden (β = −.29, p =.007). Utility scores did not significantly change after 24–36 months of survival, and the utilities of survivors were comparable to the matched control population (0.84 vs 0.87; p =.07). Discussion: Our results show that long-term advanced melanoma survivors treated with ipilimumab monotherapy experience relatively stable and high health-state utility scores. [ABSTRACT FROM AUTHOR] |
| Copyright of Quality of Life Research is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background: Checkpoint inhibitors have been shown to substantially improve the survival of patients with advanced melanoma. With this growing group of survivors treated with immunotherapies, assessing their health-state utilities is essential and can be used for the calculation of quality-adjusted life years and for cost-effectiveness analyses. Therefore, we evaluated the health-state utilities in long-term advanced melanoma survivors. Methods: Health-state utilities were evaluated in a cohort of advanced melanoma survivors 24–36 months (N = 37) and 36-plus months (N = 47) post-ipilimumab monotherapy. In addition, the health-state utilities of the 24–36 months survivor group were assessed longitudinally, and utilities of the combined survival groups (N = 84) were compared with a matched control population (N = 168). The EQ-5D was used to generate health-state utility values, and quality-of-life questionnaires were used to establish correlations and influencing factors of utility scores. Results: Health-state utility scores were similar between the 24–36 months'- and the 36-plus months' survival group (0.81 vs 0.86; p =.22). In survivors, lower utility scores were associated with symptoms of depression (β = −.82, p =.022) and fatigue burden (β = −.29, p =.007). Utility scores did not significantly change after 24–36 months of survival, and the utilities of survivors were comparable to the matched control population (0.84 vs 0.87; p =.07). Discussion: Our results show that long-term advanced melanoma survivors treated with ipilimumab monotherapy experience relatively stable and high health-state utility scores. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 09629343 |
| DOI: | 10.1007/s11136-023-03427-9 |
